Real-world data from 3318 patients with CRSwNP showed persistence with dupilumab at 84.9% and 69.5% at 6 and 12 months, respectively.
Among patients who discontinued dupilumab, over 40% restarted treatment within 12 months, with a median reinitiation interval of 1.2 months.
Adherence rate was high, with 75.2% of patients achieving a medication possession ratio ≥ 0.8 during the 12-month follow-up.
Findings support sustained use and real-world effectiveness of dupilumab for CRSwNP and highlight the need for further study of persistence patterns in various patient subgroups.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.